Genitourinary Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Genitourinary Drugs Market is Segmented by Disease Type, Drug Type, and Geography

Market Snapshot

Picture1 Genitourinary Drugs Market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 2.6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The growing prevalence of genitourinary disorders and increasing number of pipeline drugs are expected to widen the market growth, globally. In addition, the rising disposable incomes and constant improvements in healthcare infrastructure, increase in investments in R&D activities in developing novel molecules for the treatment of genitourinary diseases, and the increasing number of pipeline drugs are also expected to drive the market, during the forecast period. 

However, an increasing number of counterfeit drugs and lack of awareness about the infections and drugs for the treatment are going to restrain the market for genitourinary drugs.

Scope of the Report

As per the scope of the report, genitourinary drugs are the drugs that are used to treat disorders affecting the kidneys, bladder, ureters, and urethra. Since long, patients suffering from disorders and infections related to genitourinary systems have been depending on steroids and immunosuppressants which are chemically synthesized and may reciprocate with some serious side effects such as insomnia, acne, nausea, vomiting, and diarrhea. As a result, patients are now turning to biological drugs that not only cause no side-effects, but are also more effective in the treatment of genitourinary infections.

By Disease Type
Erectile dysfunction
Gonorrhoea
Genital Herpes
Urinary Tract Infections
Urinary Incontinence
Glomerulonephritis
Chronic renal failure
Other Disease Types
By Drug Type
Hormonal Therapy
Impotence Agents
Uterine Relaxants
Urinary Antispasmodics
Urinary pH Modifiers
Uterine Stimulants
Miscellaneous Genitourinary Tract Agents
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East & Africa
GCC
South Africa
Rest of Middle-East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Urinary Tract Infections are Expected to Dominate the Genitourinary Drugs Market

As there is an increase in the incidence of urinary tract infections, the demand for genitourinary drugs increases, which, in turn helps in driving the overall market. Furthermore, the launch of combination drugs, development, and approval of new drugs, which are more efficient, and the increasing geriatric population are also expected to boost the growth of the urinary tract infection segment in the global genitourinary drugs market.

Additionally, the genitourinary drugs market is also expected to gain from increasing incidences of urinary diseases and related illness that are sexually transmitted. Moreover, rising concerns about urinary incontinence and impotency as well as technological advancements in genitourinary devices are anticipated to accentuate the growth of the global genitourinary drugs market over the forecast period.

Picture3.png

Asia Pacific is Expected to be the Fastest Growing Region During the Forecasted Period

Asia is expected to experience a high growth rate in the genitourinary drugs market in the next few years, due to rise in genitourinary disease cases, growing need for improved treatments and therapies of genitourinary diseases, increasing awareness about genitourinary diseases, rise in health care expenditure, and developing health care infrastructure in the region. Growing demographics and economies in the developing countries, such as India and China, are expected to lead to the rise of the genitourinary drugs market in the Asia-Pacific region.

Picture4.png

Competitive Landscape

Major market players are found investing high capitals on R&D and generating many strategies, such as new product launches and developments, geographical expansions, collaborations, and acquisitions to strengthen their market position in the global genitourinary drugs market. 

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Genitourinary Disorders

      2. 4.2.2 Rising Disposable Incomes and Constant Improvements in Healthcare Infrastructure

      3. 4.2.3 Increasing Number of Pipeline Products

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Therapy Compliance

      2. 4.3.2 Increasing Advent of Counterfeit Drugs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Disease Type

      1. 5.1.1 Erectile dysfunction

      2. 5.1.2 Gonorrhoea

      3. 5.1.3 Genital Herpes

      4. 5.1.4 Urinary Tract Infections

      5. 5.1.5 Urinary Incontinence

      6. 5.1.6 Glomerulonephritis

      7. 5.1.7 Chronic renal failure

      8. 5.1.8 Other Disease Types

    2. 5.2 By Drug Type

      1. 5.2.1 Hormonal Therapy

      2. 5.2.2 Impotence Agents

      3. 5.2.3 Uterine Relaxants

      4. 5.2.4 Urinary Antispasmodics

      5. 5.2.5 Urinary pH Modifiers

      6. 5.2.6 Uterine Stimulants

      7. 5.2.7 Miscellaneous Genitourinary Tract Agents

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Eli Lilly and Company

      2. 6.1.2 GlaxoSmithKline PLC

      3. 6.1.3 Cipla USA Inc.

      4. 6.1.4 Melinta Therapeutics Inc.

      5. 6.1.5 Allergan PLC

      6. 6.1.6 Merck & Co. Inc.

      7. 6.1.7 Novartis AG

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 Genentech, Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Genitourinary Drugs Market market is studied from 2018 - 2026.

The Genitourinary Drugs Market is growing at a CAGR of 2.6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Melinta Therapeutics Inc., Cipla USA Inc., Allergan PLC, Merck & Co. Inc., Pfizer Inc. are the major companies operating in Genitourinary Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!